Proinflammtory cytokine production is blocked by ruxolitinib treatment. (A) The TNF-α and IL-12 levels determined in the serum on days 4, 8, 14, and 109 after allo-HCT in untreated mice or recipients treated with vehicle or ruxolitinib. The data are pooled from 2 independent experiments with at least 5 mice per group. (B-C) Serial luciferase–specific imaging was performed with BALB/c WT mice that had undergone allo-HCT with WT BM and luc⁺ CD4/CD8 T cells. The experiment was performed twice and 1 representative experiment is shown in (B). In (C) the respective P values for the individual time points and the number of mice in each group are indicated in the graph. (D) The organs small intestines, large intestines, and liver were isolated on d109 after allo-HCT from ruxolitinib-treated mice or from untreated mice, and histopathologic changes were scored as described in the Material and methods section. (E) The organs, small intestines, spleen, and liver were isolated on day 14 after allo-HCT, and the absolute numbers (spleen) or frequencies (small intestine and liver) of CD4 and CD8 T cells were determined. The number of mice is indicated for each group.